0
0

Sections

Excerpt

Club drugs, which are sometimes called "party drugs," are a disparate group of psychoactive substances that include methylenedioxymethamphetamine (MDMA), ketamine, and gamma-hydroxybutyrate (GHB), among others. These drugs differ in terms of administration, mechanism of action, and effect. What unites them, and why they are grouped together here, is that in many cases they are used by groups of younger people in social settings, often at raves or parties. They are often taken in various combinations. Polysubstance use might be considered the norm at such events, with more than 80% of participants using more than one illicit substance (Boys et al. 1997; Winstock et al. 2001).

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

References

Ajaelo I, Koenig K, Snoey E: Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. Academic Emergency Medicine 5:839–840, 1998
[PubMed]
 
Ames D, Wirshing W: Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome—a possible link? JAMA 269:869–870, 1993
[PubMed]
 
Beck J, Rosenbaum M: Pursuit of Ecstasy: The MDMA experience. Albany, NY, State University of New York Press, 1994
 
Boys A, Lenton S, Norcross K: Polydrug use at raves by a Western Australian sample. Drug Alcohol Review 16:227–234, 1997
[PubMed]
 
Burgess C, O'Donoghoe A, Gill M: Agony and ecstasy: a review of MDMA effects and toxicity. European Psychiatry 15:287–294, 2000
[PubMed]
 
Chin MY, Kreutzer RA, Dyer JE: Acute poisoning from gamma-hydroxybutyrate in California. West J Med 156:380–384, 1992
[PubMed]
 
Cohen R: The Love Drug: Marching to the Beat of Ecstasy. Binghamton, NY, Hayworth Press, 1998
 
Cooper M: "Special K": rough catnip for clubgoers. New York Times, January 28, 1996, p A-6
 
Cotman CW, Monaghan DT: Chemistry and anatomy of excitatory amino acid systems, in Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York, Raven, 1987, pp 194–210
 
Curran HV, Monaghan L: In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 96:749–760, 2001
[PubMed]
 
Delgarno PJ, Shewan D: Illicit use of ketamine in Scotland. J Psychoactive Drugs 28:191–199, 1996
 
Demirkiran M, Jankovic J, Dean J: Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clinical Neuropharmacol 19:157–164, 1996
[PubMed]
 
Dotson J, Ackerman D, West L: Ketamine abuse. J Drug Issues 25:751–757, 1995
 
Eisner B: Ecstasy: The MDMA Story. Boston, MA, Little, Brown, 1986
 
Eisner B: Ecstasy: The MDMA Story, 2nd Edition. Berkeley, CA, Ronin Publishing, 1993
 
Gallimberti L, Gentile N, Cibin M, et al: Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet 30:787–789, 1989
 
Galloway GP, Frederick SL, Staggers FE, et al: Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 92:89–96, 1997
[PubMed]
 
Garfield JM, Garfield FB, Stone JG, et al: A comparison of psychologic responses to ketamine and thiopental–nitrous oxide–halothane anesthesia. Anesthesiology 36:329–338, 1994
 
Graeme KA: New drugs of abuse. Emerg Med Clin North Am 18(4):625–636, 2000
[PubMed]
 
Green A, Cross A, Goodwin G: Review of pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"). Psychopharmacology 119:247–260, 1995
[PubMed]
 
Hechler V, Goebaille S, Maitre M: Selective distribution pattern of gamma-hydroxybutyrate receptors in the rat forebrain and mid-brain as revealed by quantitative autoradiograph. Brain Res 572:345–348, 1992
[PubMed]
 
Hermle L, Spitzer M, Borchardt K, et al: Psychological effects of MDE in normal subjects. Neuropsychopharmacology 8:171–176, 1993
[PubMed]
 
Holmes SB, Banerjee AK, Alexander WD: Hyponatremia and seizures after ecstasy use. Postgrad Med J 75:32–43, 1999
[PubMed]
 
Jansen KLR: Ketamine—can chronic use impair memory? International Journal of the Addictions 25:133–139, 1990
[PubMed]
 
Kalant H: The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. Can Med Assoc J 165:917–928, 2001
[PubMed]
 
Krystal JH, Karper LP, Seityl JP, et al: Subanesthetic effects of the noncompetitive NMDA antagonist ketamine in humans. Arch Gen Psychiatry 51:199–214, 1994
[PubMed]
 
Liester MB, Grob CS, Bravo GL, et al: Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis 180:345–354, 1992
[PubMed]
 
Malhotra AK, Pinals DA, Weingartner H, et al: NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301–307, 1996
[PubMed]
 
McCabe E, Layne E, Sayler D, et al: Synergy of ethanol and a natural soporific: gamma hydroxybutyrate. Science 171:404–406, 1971
[PubMed]
 
McCann U, Ricaurte G: Reinforcing subjective effects of 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence. J Clin Psychopharmacol 13:214–217, 1993
[PubMed]
 
McCann UD, Ridenour A, Shaham Y, et al: Serotonin neurotoxicity after (±)3,4-methylenedioxymethamphetamine (MDMA; "ecstasy"): a controlled study in humans. Neuropsychopharmacology 10:129–138, 1994
[PubMed]
 
McCann UD, Eligulashvili W, Ricaurte GA: (+/-) 3,4-Methylenedioxymethamphetamine ("ecstasy")-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 42:11–16, 2000
[PubMed]
 
McDowell DM: Testimony to House Judiciary Committee, 1998. Available at: http://www.house.gov/judiciary/mcdo0615.htm. Accessed February 1, 2004.
 
Montoya A, Sorrentino R, Lucas S, et al: Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review. Harv Rev Psychiatry 10:212–220, 2002
[PubMed]
 
Morgan MJ: Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152:230–248, 2000
[PubMed]
 
Óye N, Paulsen O, Maurset A: Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 260:1209–1213, 1992
 
Peroutka S, Newman H, Harris H: Subjective effects of 3,4-MDMA in recreational abusers. Neuropsychopharmacology 11:273–277, 1998
 
Rattray M: Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. Essays in Biochemistry 26:77–87, 1991
[PubMed]
 
Rodgers J: Cognitive performance amongst recreational users of "ecstasy." Psychopharmacology 151:19–24, 2000
[PubMed]
 
Schwartz RH, Mille NS: MDMA (ecstasy) and the rave: a review. Pediatrics 100:705–708, 1997
[PubMed]
 
Shulgin A: The background and chemistry of MDMA. J Psychoactive Drugs 18:291–304, 1986
[PubMed]
 
Siegel RK: The natural history of hallucinogens, in Hallucinogens: Neurochemistry, Behavioral, and Clinical Perspectives. Edited by Jacobs BL. New York, Raven Press, 1984, pp 1–17
 
Sprague JE, Everman SL, Nichols DE: An integrated hypothesis for the serotonergic axonal loss induced by 3,4- methylenedioxymethamphetamine. Neurotoxicology 19:427–441, 1998
[PubMed]
 
Takahara J, Yunoki S, Yakushiji W, et al: Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab 44:1014, 1977
[PubMed]
 
Turner JJ, Parrott AC: "Is MDMA a human neurotoxin?" Diverse views from the discussants. Neuropsychobiology 42:42–48, 2000
[PubMed]
 
Verkes RJ, Gijsman HJ, Pieters MS, et al: Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 153:196–202, 2001
[PubMed]
 
Vickers MD: Gamma-hydroxybutyric acid. International Anesthesiology Clinics 71:75–89, 1969
 
Winstock AR, Griffiths P, Stewart D: Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 64:9–17, 2001
[PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 4.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 7.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 8.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 10.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 4.  >
Psychiatric News
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation